Medtronic plc

NYSE:MDT Stock Report

Market Cap: US$128.0b

Medtronic Future Growth

Future criteria checks 1/6

Medtronic is forecast to grow earnings and revenue by 9.3% and 5.4% per annum respectively. EPS is expected to grow by 9.2% per annum. Return on equity is forecast to be 16.1% in 3 years.

Key information

9.3%

Earnings growth rate

9.21%

EPS growth rate

Medical Equipment earnings growth13.6%
Revenue growth rate5.4%
Future return on equity16.08%
Analyst coverage

Good

Last updated11 Dec 2025

Recent future growth updates

Medtronic plc Just Recorded A 13% EPS Beat: Here's What Analysts Are Forecasting Next

Nov 28
Medtronic plc Just Recorded A 13% EPS Beat: Here's What Analysts Are Forecasting Next

Recent updates

Medtronic: This Dividend Aristocrat Is Just Getting Started

Dec 09

Medtronic plc Just Recorded A 13% EPS Beat: Here's What Analysts Are Forecasting Next

Nov 28
Medtronic plc Just Recorded A 13% EPS Beat: Here's What Analysts Are Forecasting Next

Medtronic's (NYSE:MDT) Solid Earnings Are Supported By Other Strong Factors

Sep 03
Medtronic's (NYSE:MDT) Solid Earnings Are Supported By Other Strong Factors

Medtronic's (NYSE:MDT) Returns On Capital Are Heading Higher

Jul 07
Medtronic's (NYSE:MDT) Returns On Capital Are Heading Higher

A Look At The Fair Value Of Medtronic plc (NYSE:MDT)

Jun 16
A Look At The Fair Value Of Medtronic plc (NYSE:MDT)

Medtronic (NYSE:MDT) Will Pay A Larger Dividend Than Last Year At $0.71

May 30
Medtronic (NYSE:MDT) Will Pay A Larger Dividend Than Last Year At $0.71

Medtronic: One Of The Best Times To Buy

Apr 21

Is Now An Opportune Moment To Examine Medtronic plc (NYSE:MDT)?

Apr 14
Is Now An Opportune Moment To Examine Medtronic plc (NYSE:MDT)?

Medtronic: A Great Business, But With Low Growth

Mar 27

Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy

Mar 20

Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+

Strengths and Competitive Advantages:Diverse Product Portfolio: Medtronic operates across four key segments—Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes—providing revenue stability and

Medtronic (NYSE:MDT) Has More To Do To Multiply In Value Going Forward

Feb 17
Medtronic (NYSE:MDT) Has More To Do To Multiply In Value Going Forward

Medtronic: Several Reasons For Optimism Before The Upcoming Earnings Release

Feb 15

Medtronic: Undervalued But Underperforming - Why Innovation Isn't Enough To Lift The Stock

Feb 07

We Think Medtronic (NYSE:MDT) Can Stay On Top Of Its Debt

Jan 20
We Think Medtronic (NYSE:MDT) Can Stay On Top Of Its Debt

Medtronic: A Dividend Aristocrat That's Poised To Pop

Jan 06

Investors Appear Satisfied With Medtronic plc's (NYSE:MDT) Prospects

Jan 06
Investors Appear Satisfied With Medtronic plc's (NYSE:MDT) Prospects

Medtronic Stock Is Still A Great "Buy"

Dec 26

Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing

Nov 19

Medtronic: Undervalued But Trapped In Slow Growth (Rating Downgrade)

Oct 31

Medtronic: Undervalued Dividend Aristocrat With High Margins

Oct 10

Earnings and Revenue Growth Forecasts

NYSE:MDT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
4/30/202840,1616,5737,2679,40514
4/30/202738,1606,0406,6148,78416
4/30/202636,0595,3945,8337,79916
10/24/202534,7584,7645,2067,113N/A
7/25/202534,2004,6605,3037,146N/A
4/25/202533,5374,6625,1857,044N/A
1/24/202533,1994,2605,4677,293N/A
10/25/202432,9964,2885,4997,195N/A
7/26/202432,5773,9275,1456,898N/A
4/26/202432,3643,6765,2006,787N/A
1/26/202432,3204,2014,9316,470N/A
10/27/202331,9584,1024,0455,570N/A
7/28/202331,5583,6204,4445,831N/A
4/28/202331,2273,7584,5806,039N/A
1/27/202330,7714,0644,1665,636N/A
10/28/202230,8064,3214,8226,290N/A
7/29/202231,0705,2055,7217,137N/A
4/29/202231,6865,0395,9787,346N/A
1/28/202231,7854,9145,6787,034N/A
10/29/202131,7984,7045,7737,162N/A
7/30/202131,5973,8825,8557,254N/A
4/30/202130,1173,6064,8856,240N/A
1/29/202127,9262,8924,6315,945N/A
10/30/202027,8683,5374,7525,996N/A
7/31/202027,9274,4124,7566,002N/A
4/24/202028,9134,7896,0217,234N/A
1/24/202031,0625,4086,6597,871N/A
10/25/201930,8914,7626,2987,519N/A
7/26/201930,6664,420N/A6,815N/A
4/26/201930,5574,631N/A7,007N/A
1/25/201930,5554,826N/A5,958N/A
10/26/201830,3782,168N/A5,905N/A
7/27/201829,9473,163N/A5,649N/A
4/27/201829,9533,104N/A4,684N/A
1/26/201829,7252,859N/A5,419N/A
10/27/201729,6395,069N/A5,502N/A
7/28/201729,9344,115N/A6,067N/A
4/28/201729,7104,028N/A6,880N/A
1/27/201729,3613,968N/A6,433N/A
10/28/201629,0124,242N/A6,145N/A
7/29/201628,7253,647N/A5,952N/A
4/29/201628,8333,538N/A5,218N/A
1/29/201628,4352,434N/A5,804N/A
10/30/201525,8192,316N/A5,774N/A
7/31/201523,1272,624N/A5,408N/A
4/24/201520,2612,675N/A4,902N/A
1/23/201517,4103,124N/A4,318N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDT's forecast earnings growth (9.3% per year) is above the savings rate (3.3%).

Earnings vs Market: MDT's earnings (9.3% per year) are forecast to grow slower than the US market (16.1% per year).

High Growth Earnings: MDT's earnings are forecast to grow, but not significantly.

Revenue vs Market: MDT's revenue (5.4% per year) is forecast to grow slower than the US market (10.6% per year).

High Growth Revenue: MDT's revenue (5.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MDT's Return on Equity is forecast to be low in 3 years time (16.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/15 06:15
End of Day Share Price 2025/12/15 00:00
Earnings2025/10/24
Annual Earnings2025/04/25

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medtronic plc is covered by 51 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kadambari DaptardarAccountability Research Corporation
Harshit GuptaAccountability Research Corporation
David ToungArgus Research Company